<DOC>
	<DOCNO>NCT00673920</DOCNO>
	<brief_summary>This study evaluate efficacy safety ocrelizumab , compare placebo , patient active rheumatoid arthritis inadequate response methotrexate therapy . Patients randomize 2:2:1 receive 1 ) infusion ocrelizumab 200mg iv Days 1 15 , 2 ) infusion ocrelizumab 400mg iv Day 1 placebo iv Day 15 , 3 ) infusion placebo iv Days 1 15 . At end placebo-controlled treatment period 24 week , patient group 1 3 re-randomized receive either single infusion 400mg iv ocrelizumab 2 infusion 200mg iv ocrelizumab , group 2 receive second single infusion 400mg iv ocrelizumab . All patient receive stable dose concomitant methotrexate ( 7.5-25mg/week ) throughout study . The anticipated time study treatment 1-2 year . Target number patient enrol trial 300 .</brief_summary>
	<brief_title>A Study Evaluate Ocrelizumab Compared With Placebo Patients With Rheumatoid Arthritis Who Have Inadequate Response Methotrexate Therapy</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<criteria>Inclusion criterion : Adult patient , â‰¥ 18 year age Active rheumatoid arthritis Inadequate treatment DMARD methotrexate Exclusion criterion : Rheumatic autoimmune disease inflammatory joint disease rheumatoid arthritis Concurrent treatment DMARD methotrexate Previous treatment celldepleting therapy Any surgical procedure past 12 week , plan within 48 week baseline</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>RA</keyword>
</DOC>